Fig. 3

Bioenrichment, immune cell infiltration and immunotherapy efficacy prediction of two cholesterol metabolic subtypes. A Gene Set Variation Analysis (GSVA) of two subtype-related pathways in the ACRG cohort. B Gene Set Enrichment Analysis (GSEA) of differential genes of two subtypes in the ACRG cohort (CMT2 versus CMT1). C‒F Comparison of the ESTIMATE score, Immune score, Stromal score and tumor purity of the two subtypes in the ACRG cohort (Wilcoxon test). G Comparison of immune cell infiltration between the two subtypes in the ACRG cohort (ssGSEA, Wilcoxon test). H The proportions of infiltrating immune cells in the two subtypes were determined using the CIBERSORT tool. I Expression levels of immune checkpoint genes in the TCGA-STAD cohort. J Tumor mutation burden in the two subtypes in the TCGA-STAD cohort. K TIDE scores in the two subtypes in the TCGA-STAD cohort. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001